Last reviewed · How we verify

GW679769 (casopitant) — Competitive Intelligence Brief

GW679769 (casopitant) (GW679769 (casopitant)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK1 receptor antagonist. Area: Oncology.

phase 3 NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GW679769 (casopitant) (GW679769 (casopitant)) — GlaxoSmithKline. Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the brain to prevent chemotherapy-induced nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GW679769 (casopitant) TARGET GW679769 (casopitant) GlaxoSmithKline phase 3 NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor)
Akynzeo solution Akynzeo solution Helsinn Healthcare SA marketed NK1 receptor antagonist / 5-HT3 receptor antagonist combination NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
Fosaprepitant for Injection Fosaprepitant for Injection Montefiore Medical Center marketed NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor)
Aprepitant plus Ondansetron Aprepitant plus Ondansetron University of Pittsburgh marketed NK1 receptor antagonist + 5-HT3 receptor antagonist combination NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
fosnetupitant/ palonosetron fosnetupitant/ palonosetron Helsinn Healthcare SA marketed NK1 receptor antagonist / 5-HT3 receptor antagonist combination NK1 receptor (substance P receptor) / 5-HT3 receptor
Pro-netupitant/Palonosetron Pro-netupitant/Palonosetron Helsinn Healthcare SA phase 3 NK1 receptor antagonist and 5-HT3 receptor antagonist NK1 receptor and 5-HT3 receptor
MK0869, aprepitant MK0869, aprepitant Merck Sharp & Dohme LLC phase 3 NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK1 receptor antagonist class)

  1. Merck Sharp & Dohme LLC · 4 drugs in this class
  2. GlaxoSmithKline · 3 drugs in this class
  3. Organon and Co · 3 drugs in this class
  4. CCTU · 2 drugs in this class
  5. Acacia Pharma Ltd · 2 drugs in this class
  6. Sanofi · 1 drug in this class
  7. Santen SAS · 1 drug in this class
  8. CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class
  9. Montefiore Medical Center · 1 drug in this class
  10. New Mexico Cancer Research Alliance · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GW679769 (casopitant) — Competitive Intelligence Brief. https://druglandscape.com/ci/gw679769-casopitant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: